Breaking Hedge Fund News






Each business day HedgeCo.Net keeps you informed with the top hedge fund industry news, opinion and insight from around the globe. From the latest hedge fund launches, to the impact of regulation, competition, and investor activism - we track the topics and people that make a difference to you.

Explore the most informative hedge fund articles and take the news with you, using HedgeCo's Hedge Fund News RSS

Still want more? Browse the hedge fund blogs, authored by hedge fund industry experts.


News Categories
Today is Sunday, February 12, 2012 at 
- Countdown to Market Close:
Posts Tagged ‘early monday’

Gold Falls Hard vs. Dollar as Stocks & Commodities Sink, Faces “Definite Downside Risks”

Monday, August 17, 2009 : Permalink

BullionVault – The Gold Price fell sharply against a strong US Dollar on Monday morning, falling through what one Asian dealer called "technical and psychological support at $942" to record the lowest Gold Fix so far this month at $937.50 an ounce.

Crude oil sank below $66 per barrel, while base metals and silver lost more than 3%.

Adding to Friday’s 0.7% loss despite news that France and Germany crept out of recession between April and July, world stock markets sank 1.4% early Monday on average – the biggest one-day loss in more than six weeks – after Japan reported 0.9% growth in its second-quarter GDP.

Read Complete Article

Tags: , , , , , , , , , , , , , ,

trackback from your site.

Indevus soars on drug, hedge fund news

Tuesday, March 3, 2009 : Permalink

Boston Business Journal – Just days after winning regulatory approval for the manufacture and marketing of its cancer therapy for bladder cancer, Indevus Pharmaceuticals Inc. disclosed that a North Carolina hedge fund has acquired 8.5 percent of its common stock.

Lexington, Mass.-based Indevus made the announcements via regulatory filings late Friday and early Monday with the Securities and Exchange Commission.

On Friday, the company said the U.S. Food and Drug Administration had approved its supplemental new drug application for Valstar, a therapy that aims to treat bladder cancer through an injectable technology.

Valstar was first approved by the FDA in 2002, however design as well as manufacturing issues have prevented Indevus from marketing the drug in the United States since 2002.

Indevus said it intends to market Valstar during the second half of this year.

Read Complete Article

 

Related Posts Plugin for WordPress, Blogger...

Tags: , , , , , , , , , , , , , , , , ,

trackback from your site.